Visfatin levels in non-obese, obese, and insulin resistant adolescents

Indra Ihsan; Eka Agustia Rini; Rismawati Yaswir

doi:10.14238/pi56.5.2016.291-6

Indra Ihsan Departement of Child Health, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia.
Eka Agustia Rini Departement of Child Health, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia.
Rismawati Yaswir Departement of Clinical Pathology, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia

DOI: https://doi.org/10.14238/pi56.5.2016.291-6

Keywords: obese adolescents, insulin resistance, visfatin

Abstract

Background Adipose tissue is not merely a site for energy storage, but is also the largest endocrine organ, secreting various adipocytokines. Plasma visfatin, an adipocytokine predominantly secreted from visceral adipose tissue, has insulin-mimetic effects, and has been closely linked to insulin resistance.

Objective To compare plasma visfatin levels between obese and non-obese adolescents, as well as between obese adolecents with and without insulin resistance.

Methods This cross-sectional study was conducted in students who attended three senior high schools in Padang. Subjects comprised 28 obese and 28 non-obese adolescents. The age of the subjects ranged from 14-18 years. Obesity criteria were based on body mass index (BMI) measurements. Fasting serum glucose level was measured by glucose hexokinase photometry and serum insulin was measured by chemiluminesence immunoassay. Plasma visfatin was measured by enzyme-linked immunosorbent assay (ELISA). The insulin resistance index was estimated from fasting serum insulin and glucose levels using the homeostatic model assessment for insulin resistance (HOMA-IR). Differences in the variables were tested using independent T-test and Mann-Whitney test, depending on the distribution of the variables.

Results The mean plasma visfatin level was significantly higher in the obese than in the control group [2.55 (SD 1.54) vs. 1.61 (SD 0.64) ng/mL, respectively; (P=0.005)]. The insulin resistant group had significantly higher mean plasma visfatin level than the non-resistant group [3.61 (SD 1.59) vs. 1.96 (SD 1.18) ng/mL, respectively; (P=0.004)].

Conclusion Obese adolescents with insulin resistance have signifcantly higher plasma visfatin levels compared to those without insulin resistance.

Author Biography

Eka Agustia Rini, Departement of Child Health, Andalas University, Dr. M. Djamil Hospital, Padang, Indonesia.

pediatric endocrinologist

References

1. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426â€“30.
2. Curat CA, Wegner V, Sengene`s C, Miranville A, Tonus C, Busse R, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49:744â€“7.
3. Chung HM, Won CH, Sung JH. Responses of adipose-derived stem cells during hypoxia: enhanced skin-regenerative potensial. Expert Opin Biol Ther. 2009;9:1499-508.
4. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang JO, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett. 2006;580:4105-13.
5. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/PBEF/ Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6:363â€“75.
6. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Muller M, Wolzt M. Exercise training lower plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab. 2006;91:4702-4.
7. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract. 2008;79:412-8.
8. Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, Kawada Y, et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity. 2008;16:384-8.
9. Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H, et al. Plasma visfatin concentrations in childhood obesity: relationship to insulin resistance and antropometric indices. Swiss Med Wkly. 2009;139:22-7.
10. Mahaweerawat U, Somdee T, Sungkamanee S, Yangyuen S. Serum visfatin concentration and biochemistry parameter relationship of obese adolescents in Thailand. KKU Res J. 2010;15:155-9.
11. Tascilar ME, Cekmez F, Meral C, Pirgon O, Tanju IA, Canpolat FE, et al. Evaluation of adipocytokines in obese children with insulin resistance. Turk J Pediatr. 2011;53:269-73.
12. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-Î² cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91:3165-70.
13. Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M, et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med. 2006;23:967-73.
14. Kolsgaard ML, Wangensteen T, Brunborg C, Joner G, Holven KB, Halvorsen B, et al. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome. Scand J Clin Lab Invest. 2009;69:858-64.
15. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol. 2007;157:437-42.
16. Zhu J, Schott M, Liu R, Liu C, Shen B, Wang Q, et al. Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res. 2008;40:801-5.
17. El-Shafey EM, El-Nagger GF, Al-Bedewy MM, El-Sorogy HE. Is there a relationship between visfatin level and type 2 diabetes mellitus in obese and non obese patients? J Diabetes Metab. 2012;11:1-5.
18. Dinisari A, Asdie AH, Wachid DN. Kadar visfatin pada orang obes visceral. Berkala Kesehatan Klinik. 2009;15:7-12.
19. Ogden CL, Flegal KM. Changes in terminology for childhood overweight and obesity. Natl Health Stat Report. 2010; 25:1â€“5.
20. Singh Y, Garg MK, Tandon N, Marwaha RK. A study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J Clin Res Pediatr Endocrinol. 2013;5:245-51.
21. Kementrian Kesehatan Republik Indonesia. Riset Kesehatan Dasar (RISKESDAS) 2013. Jakarta: Kemenkes RI; 2013. p. 218-23.
22. Adhianto G, Soetjiningsih. Prevalence and risk factors of overweigh and obesity in adolescent. Paediatr Indones. 2002;42:206-11.
23. Andriani E. Hubungan kadar omentin-1 dengan resistensi insulin pada remaja obesitas di kota Padang. [Thesis]. [Padang]: Fakultas Kedokteran Universitas Andalas; 2015.
24. Pulungan BA, Puspitadewi A, Sekartini R. Prevalence of insulin resistance in obese adolescents. Paediatr Indonesiana. 2013;53:167-72
25. Lestari R. Hubungan nilai homeostasis model assesment of insulin resistance dengan acanthosis nigricans dan tekanan darah pada remaja obesitas di Kota Padang. [Thesis]. [Padang]: Fakultas Kedokteran Universitas Andalas; 2010.
26. Caceres M, Teran CG, Rodriguez S, Medina M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescent with obesity. BMC Pediatr. 2008;8:31
27. Siddiqui SA, Bashir S, Shabbir I, Sherwani MK, Aasim M. Association of insulin resistance with obesity in children. Pak J Med Res. 2011;50:137-40.
28. Ghergherechi R, Tabrizi A. Prevalence of impaired glucose tolerance and insulin resistance among obese children and adolescents. Ther Clin Risk Manag. 2010;6:345â€“9.
29. Alberti SG, Zimmet P, Kaufman F, Tajima N, Slilink M, Arslanian S, et al. The IDF consensus definition of the metabolic syndrome in children and adolescents. Pediatric Diabetes. 2007;2:1-20.
30. Gobato AO, Vasques AC, Zambon MP, Barros Filho Ade A, Hessel G. Metabolic syndrome and insulin resistance in obese adolescents. Rev Paul Pediatr. 2014;32:55-62.
31. Chiarelli F, Marcovecchio ML. Insulin resistance and obesity in chilhood. Eur J Endocrinol. 2008;159:67â€“74.
32. Steinberger J, Daniels SR, American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young); American Heart Association Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Obesity, insulin resistance, diabates and cardiovascular risk in children. Circulation. 2003;107:1448-53.
33. Krzystek-Korpacka M, Patryn E, Bednarz-Misa I, Hotowy K, Noczynska A. Visfatin in juvenile obesity-the effect of obesity intervention and sex. Eur J Clin Invest. 2011;41:1284â€“91.
34. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54:2911-6.
35. Nourbakhsh M, Nourbakhsh M, Gholinejad Z, Razzaghry-Azar M. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Scand J Clin Lab Invest. 2015;75:183-8.
36. Chang YC, Chang TJ, Lee WJ, Chuang LM. The relationship of visfatin/pre-Î² cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance and plasma lipids. Metabolism. 2010;59:93-9.
37. DivkoviÄ‡ D, RelatiÄ‡ KS, Ä†osiÄ‡ A, DrenjanÄeviÄ‡ I, Kristek J, RadiÄ‡ R. Serum visfatin concentration in eutrophic and overweight/obese male children in early childhood. Periodicum Biologorum. 2014;116:191-6.